Gibson, William S. http://orcid.org/0000-0003-4262-4893
Rodriguez, Oscar L.
Shields, Kaitlyn
Silver, Catherine A.
Dorgham, Abdullah
Emery, Matthew
Deikus, Gintaras
Sebra, Robert
Eichler, Evan E. http://orcid.org/0000-0002-8246-4014
Bashir, Ali
Smith, Melissa L.
Watson, Corey T. http://orcid.org/0000-0001-7248-8787
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04, AI138963-04)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (HG010169, HG010169)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 22 July 2022
Revised: 7 October 2022
Accepted: 13 October 2022
First Online: 21 December 2022
Competing interests
: EEE is a scientific advisory board (SAB) member of Variant Bio, Inc. Robert Sebra is VP of Technology Development at Sema4.